PMPRB's mandate, when it was originally set up, was to ensure that price increases of patented medicines did not exceed the consumer price index. That was its mandate, and the industry was forced to accept that. What we've seen over the past 20 years is that they have moved to what we feel is beyond their mandate. They're moving now into looking very aggressively at introductory prices and looking at comparing those introductory prices to other lower standards. In other words, we feel they are getting into more or less the provincial jurisdiction, because as we showed you on our chart, once you get your approval after using up 10 years, if you want to get reimbursed publicly, which often you do, especially if it's a chronic therapy, you have to go through the PMPRB. You go through the common drug review. Then you go through the provinces.
The common drug review and the provinces are the ones that are more or less responsible for negotiating, although you don't use that term. They're trying to get the best available price. We think that the PMPRB now is moving into that realm, and it shouldn't. It should just be looking at non-excessiveness. So we are getting this additional regulatory burden up front, and then we're getting it still downstream even once you clear that hurdle.